Update from KAITLIN for high-risk HER2-positive early breast cancer

Bookmark and Share
Published: 29 May 2020
Views: 563
Rating:
Save
Dr Julie Gralow - University of Washington School of Medicine, Seattle, USA

Dr Julie Gralow speaks to ecancer online about her ASCO 2020 virtual presentation which discussed the KAITLIN study.

KAITLIN looked at trastuzumab emtansine (T-DM1) pertuzumab, vs trastuzumab pertuzumab taxane after anthracyclines as adjuvant therapy for high-risk HER2-positive early breast cancer (EBC).

The study did no reach its co-primary endpoints, and Dr Gralow explains why this may be, as well as some of the lessons learnt from the trial.